National Vision Holdings: MAGENTIQ EYE Secures Funding for AI Gastroenterology Innovations

MAGENTIQ EYE LTD. Secures Funding to Enhance AI-Powered Gastroenterology Tools

MAGENTIQ EYE LTD., an innovative player in the health technology sector, successfully completes its Series A funding round, which is pivotal for bolstering its presence in the U.S. and European markets. The company, founded in 2014, specializes in AI-powered decision-support software for gastroenterology, with its flagship product, MAGENTIQ-COLO™, gaining recognition for its ability to significantly enhance polyp detection and adenoma detection rates during colonoscopies. The software has received FDA and CE approval, underscoring its reliability and effectiveness in clinical settings. The successful funding round is led by aMoon, Israel's largest HealthTech investment fund, along with other prominent investors, marking a significant milestone in MAGENTIQ EYE’s journey.

CEO Dror Zur expresses optimism about the new capital infusion, indicating that it will facilitate the commercialization of MAGENTIQ-COLO™ while also advancing the company’s AI capabilities. This funding comes at a time when demand for effective diagnostic tools is surging, as evidenced by the strong interest reflected in the company’s pipeline of studies and purchase inquiries. With this investment, MAGENTIQ EYE aims to leverage enhanced resources to meet the increasing needs of healthcare professionals and patients alike. The partnership with aMoon also introduces Roy Wiesner to the board, who brings a wealth of experience in HealthTech, further strengthening the company's strategic direction.

The funding will not only support the scaling of MAGENTIQ-COLO™ but also aid in the development of additional diagnostic tools aimed at specific gastrointestinal diseases such as ulcerative colitis and early dysplasia in Barrett's esophagus. This expansion reflects MAGENTIQ EYE's commitment to improving patient outcomes globally through advanced technology. Wiesner emphasizes the software's accuracy, scalability, and flexibility across various gastrointestinal applications, positioning MAGENTIQ EYE as a leader in AI-assisted colonoscopy. The company aims to transform the landscape of health technology solutions and significantly enhance patient treatment outcomes.

In addition to its immediate goals, MAGENTIQ EYE’s focus on clinical trials for targeted diagnostic tools highlights its dedication to addressing specific healthcare challenges. This strategic approach not only enhances the company’s product offerings but also reinforces its role in advancing healthcare solutions that prioritize patient care. The successful funding round and the involvement of experienced investors signal a strong belief in MAGENTIQ EYE’s vision and potential in the health tech industry. As the company embarks on this new chapter, it is well-positioned to make a meaningful impact on global healthcare practices.